Sareum raised the money by selling 170.37mln new shares at 0.4p each – a 25% discount to Tuesday’s closing price
Newswires
Showing 25 of 6247
It said the proceeds of the subscription will be used primarily to fund the execution of its corporate strategy, including progressing Lupuzor through both corporate partnerships and regulatory pathways
With marketing authorisations secured, Clinigen’s jetlag drops and tablets can now be prescribed immediately by doctors
The ratio of the treatment arm versus placebo was two to one and mortality was assessed for a period of 30 days after surgery.
ValiRx had already been granted worldwide rights for the use of VAL201 in prostate cancer, and US officials have now allowed claims for the use of the drug in the prevention and treatment of metastatic cancer, including prostate cancer
ValiRx will pay a break fee of £212,500 to European High Growth Opportunities SF after the pair agreed to terminate the financing deal
By combining their drug discovery and validation platforms, C4X and PhoreMost hope to find drug targets that can potentially treat Parkinson’s sufferers
Motif presented three new posters, tackling iclaprim’s dosage, the diversity of patients who have taken part in clinical trials, and the antibiotic’s ability to fight off drug-resistant bacteria
Citi’s rating of ‘buy’ was reiterated with the share price target hiked to 1,450p from 1300p
With Brexit now being pushed back until October at the earliest, many of AMS’s US customers have chosen to run down the inventories built up prior to the original leaving date
Paul Ryan has been appointed as the company’s head of enterprise sales at Labskin AI, while Colin O’Sullivan joins as chief information officer, a position he previously held at the Australian Medical Association
The group's performance reflects the scale of the acquisition and delivers a substantial increase in revenue and EBITDA compared with the same period last year - the company said
The US drug developer used the UK company's London facility and its specially designed trial protocol
Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug
“The company has an aggressive growth strategy, including making targeted acquisitions and will, going forward, look to support its activities through more traditional forms of debt and equity issuance and will seek to avoid structures with variable conversion where possible.”
ReNeuron said it looks forward to "continuing to advance our clinical and business development activities in the months ahead".
The AIM-listed firm said it planned to develop MTD201 as a new product for the treatment of acromegaly and neuroendocrine tumours
ValiRX expects to pay European High Growth Opportunities Securitisation Fund up to £150,000 to terminate a subscription agreement.
For the three months ended 30 April 2019, the antibiotic developer reported an operating loss of £4.8mln, down from £6.6mln a year ago
Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector"
Online grocery company acquires Europe's largest vertical farm, based in Scunthorpe, and invests in the formation of a new joint venture with US and Dutch vertical farmers
Over the weekend The Guardian published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on Futura's MED2005 product
The FTSE All-Share-listed firm said Paul Fry, its chief financial officer, will assume the role of CEO in an interim capacity, in addition to his current responsibilities
Three-year deal guarantees market exclusivity for local partner if it hits minimum sales targets
ValiRX said it expects to announce the outcome of talks with European High Growth “shortly” and no longer intends to enter into further arrangements with the investor.
